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Abstract Congenital diarrheal disorders (CDD) are a
group of rare enteropathies related to specific genetic
defects. Infants with these disorders have chronic
diarrhea, frequently requiring parenteral nutrition sup-
port. Etiologies and prognoses are variable. We propose
a new classification of CDD into four groups, taking
into account the specific etiology and genetic defect: 1)
defects in digestion, absorption, and transport of
nutrients and electrolytes; 2) disorders of enterocyte
differentiation and polarization; 3) defects of enter-
oendocrine cell differentiation; and 4) dysregulation of
the intestinal immune response. The present review
focuses on the recent advances made in understanding
the pathophysiology of CDD that could potentially
improve the clinical approach to these conditions.
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Introduction
Congenital diarrheal disorders (CDD) are a group of
rare enteropathies related to specific genetic defects,
which are generally inherited as autosomal recessive
traits [1, 2••]. Frequently, infants with these disorders
present, early in life, with chronic diarrhea of sufficient
severity to require parenteral nutrition support. Milder
forms with subtle clinical signs that remain undiagnosed
until adulthood, when patients develop complications, are
also possible for some conditions [3••]. Despite similar
clinical presentations, the causes, management, and prog-
nosis of the various CDD are very different. The number
of conditions included in the CDD group has gradually
increased over the years, and many new genes have been
identified and functionally related to CDD. We suggest a
new classification of CDD in relation to the genetic
defects, taking into account diagnostic approach and
therapeutic management [3••]. This classification includes
four groups of CDD: 1) defects in digestion, absorption,
and transport of nutrients and electrolytes; 2) disorders of
enterocyte differentiation and polarization; 3) defects of
enteroendocrine cell differentiation; and 4) dysregulation
of intestinal immune response.
The exact incidence of these disorders remains to be
established and differs widely among populations and
geographic areas [4, 5]. In a recent nationwide Italian
study, reviewing 5,801 cases, we estimated an occurrence
rate of CDD of 1 per 2,000 hospitalized newborns. A study
from the Italian Society of Pediatric Gastroenterology,
Hepatology, and Nutrition (SIGENP) estimated that altered
modulation of the intestinal immune response and altered
enterocyte differentiation and polarization are the most
common causes of CDD [6].
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The main diseases included in the CDD group are presented
here, subdivided according to the pathogenetic mechanisms.
Tables 1 and 2 provide summary information about the
molecular bases of all conditions presenting with congenital
diarrhea of osmotic or nonosmotic nature.
Digestion, Absorption, and Transport of Nutrients
and Electrolytes
Congenital Lactase Deficiency
Lactose, a disaccharide unique to mammalian milk, is
hydrolyzed into the monosaccharides glucose and galactose
at the brush border of small intestinal enterocytes on the
villous tip by the enzyme lactase, a β-D-galactosidase
known as lactase phlorizin hydrolase (LPH) (EC 3.2.1.23)
[7]. Although LPH has structural analogies with other
α-glycosidases of the brush-border membrane, it has a
distinctive neutral β-glycosidic activity. Evidence indicates
the presence of two independent active sites in the lactase
molecule, one responsible for LPH activity and the other
associated with the phlorizin hydrolase activity. The
physiologic significance of the phlorizin hydrolase activity
is unknown; however, it has been proposed that the active
site could be involved in the hydrolysis of the glycosidic
moiety of glycosylceramides and vitamins. LPH is synthe-
sized as a polypeptide of about 220 kDa, which follows a
complex intracellular processing route involving heavy
glycosylation with N-linked and O-linked carbohydrates,
with intermediate forms displaying a molecular weight of
up to 280 kDa, and one or two proteolytic steps that render
a final mature product with a molecular weight of about
160 kDa. Congenital lactase deficiency (CLD [MIM
223000]), a severe form of lactase deficiency in which
lactase activity is very low or absent in the intestinal wall
from birth [7], seems to be more common than previously
assumed. Mutations in the lactase gene (LCT [GeneID:
3938]) were recently identified to underlie CLD in Finnish
families [8]. Of the five mutations, Y1390X was the founder
mutation present in 90% of the disease alleles. In addition,
four other family-specific mutations, S1666fsX1722,
S218fsX224, G1363S, and Q268H were identified in the
Disease Gene Function
Defects in digestion, absorption, and transport of nutrients and electrolytes
Congenital lactase deficiency LCT Lactase-phlorizin hydrolase activity
Sucrase-isomaltase deficiency EC 3.2.1.48 Isomaltase-sucrase
Maltase-glucoamylase deficiency MGAM Maltase-glucoamylase activity
Glucose-galactose malabsorption SGLT1 Na+/glucose cotransporter
Fructose malabsorption GLUT5 Fructose transporter
Fanconi-Bickel syndrome GLUT2 Basolateral glucose transporter
Cystic fibrosis CFTR cAMP-dependent Cl- channel
Acrodermatitis enteropathica SLC39A4 Zn2+ transporter
Congenital chloride-losing diarrhea SLC26A3 Cl-/base exchanger
Congenital sodium diarrhea SPINT2 Serine-protease inhibitor
Lysinuric protein intolerance SLC7A7 AA basolateral transport
Congenital bile acid diarrhea ABAT Ileal Na+/bile salt transporter
Shwachman-Diamond syndrome SBDS RNA metabolism
Enterokinase deficiency PRSS7 Proenterokinase
Trypsinogen deficiency PRSS1 Trypsinogen synthesis
Pancreatic lipase deficiency PNLIP Hydrolyzes triglycerides to fatty acids
Abetalipoproteinemia MTP Transfer lipids to apolipoprotein B
Hypobetalipoproteinemia APOB Apolipoprotein that forms chylomicrons
Chylomicron retention disease SAR1B Intracellular chylomicron trafficking
Congenital bile acid malabsorption SLC10A2 Bile salt transport
Defects of enteroendocrine cell differentiation
Enteric anendocrinosis NEUROG3 Enteroendocrine cell fate determination
Enteric dysendocrinosis Unknown Enteroendocrine cell function
Proprotein convertase 1 deficiency PCSK1 Prohormone processing
Table 1 Molecular basis of con-
genital diarrheal diseases deter-
mined by osmotic mechanismsa
a Diarrhea is considered osmotic if
luminal substances are responsible
for the induction of fluid secretion:
diarrhea ends with fasting. The
fecal ion gap > 100 mOsm suggest
this mechanism. Fecal ion gap is
calculated by a formula: fecal
osmolality (290 mOsm) – 2×
{[Na+ ]fecal+[K+ ]fecal}. In the
case of congenital chloride-losing
diarrhea, a low ion gap is due to
high fecal chloride loss
cAMP cyclic adenosine
monophosphate
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Finnish population. Very recently, four novel mutations in the
LCT gene were identified [9]. The mutations are quite evenly
distributed, covering both the pro region and the mature LPH.
The location of mutation in LCT does not seem to affect the
severity of diarrhea, and all mutations lead to a severe osmotic
diarrhea, severe dehydration, and weight loss. The phenotype
of CLD is in striking contrast with the phenotype of adult-
type hypolactasia, associated with the normal down-regulation
of lactase activity and producing mild or absent symptoms. It
is noteworthy that in these two conditions, the values of
lactase activity are partially overlapping, in spite of their
having different underlying molecular mechanisms [7].
However, symptoms are much more severe in CLD.
Sucrase-Isomaltase Deficiency
Intestinal digestion of sucrose requires hydrolysis to
glucose and fructose, which in mammalian species is
performed by the sucrase enzyme activity (EC 3.2.1.48)
of the sucrase-isomaltase (SI) complex [10]. The gene
coding for the human SI complex is located on chromo-
some 3, producing a protein with a predicted size of about
210 kDa. The mature SI is a complex composed of two
subunits: sucrase and isomaltase. The molecule is synthe-
sized as a single polypeptide with a molecular weight of
240–260 kDa. The precursor molecule is subjected to
complex intracellular glycosylation, with the addition of
N-linked and O-linked carbohydrates, but without proteol-
ysis. After glycosylation, the fully active pro-enzyme is
transported and inserted in the apical membrane of the
enterocytes via its N-terminus. In the apical membrane of
enterocytes, SI is subjected to extracellular processing by
pancreatic proteolytic enzymes present in the intestinal
lumen that cleave the complex, generating free S and
membrane-bound I subunits. The cleaved molecules remain
associated with each other through noncovalent interac-
tions. Congenital sucrase-isomaltase deficiency usually
becomes apparent after an infant is weaned and starts to
consume fruits, juices, and grains. After ingestion of
sucrose or maltose, an affected child typically will
experience stomach cramps, bloating, excess gas produc-
tion, and diarrhea. These digestive problems can lead to
failure to gain weight and grow at the expected rate (failure
to thrive) and malnutrition. Most affected children are better
able to tolerate sucrose and maltose as they get older.
Maltase-Glucoamylase Deficiency
Maltose (O-α-D-glucopyrinosyl-[1→4]-α-D-glucopyrano-
side) and longer glucose oligomers are the principal
products of amylase digestion of starches. The limited
amylolytic activities of salivary and pancreatic amylases
cause the accumulation of glucose oligomers with 2–20
residues, without significant release of free glucose mono-
mers. The enzyme MGAM, which shows a high α–1-4
glycohydrolytic activity, provides the activity necessary to
degrade these oligomers efficiently [11]. In contrast to the
endoglucanase α–1-4 activity of amylases, MGAM is an
exoglucanase that cleaves the terminal α–1-4 glycosidic
bond at the nonreducing end of amyloses and glucose
oligomers (EC 3.2.1.20). Although in human beings
MGAM contributes only about 20% of total intestinal
maltase activity (EC 3.2.1.3), the averaged Michaelis
constant (Km) of MGAM for the hydrolysis of glucose
oligomers is about 75 times lower than SI complex.
MGAM activity is therefore an efficient in vivo producer
of free glucose and is limited only by branching at α–1-6
glucosidic bonds. Thus, MGAM accounts for the bulk of the
Table 2 Molecular basis of congenital diarrheal diseases determined by nonosmotic mechanismsa
Disease Gene Function
Defects of enterocyte differentiation and polarization
Microvillous inclusion disease EpCAM Intracellular protein trafficking
Congenital tufting enteropathy Unknown Cell-cell interaction
Syndromic diarrhea Unknown Unknown
Defects of modulation of intestinal immune response
IPEX syndrome FOXP3 Transcription factor
IPEX-like syndrome Unknown Unknown
Immunodeficiency-associated autoimmune enteropathy Unknown Unknown
Autoimmune polyglandular syndrome-1 (APS-1) AIRE Regulation gene transcription
Autoimmune enteropathy with colitis-generalized autoimmune gut disorder (GAGD) Unknown Unknown
a Diarrhea is considered nonosmotic if endogenous substances induce fluid secretion: diarrhea persists even when the patient is fasting (fecal ion gap <
100 mOsm).
IPEX immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
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glucogenic activity resulting from the digestion of glucose
oligomers generated by amylase activities. The combined
activities of MGAM and SI are not rate-limiting to starch
oligomer digestion and glucose absorption. The human MGA
deficiency gene is located on the chromosome 7 [11]. The
encoded protein contains 1,857 amino acid residues that
undergo extensive N and O glycosylation, which renders a
mature protein with a molecular weight of about 335 kDa
inserted into the plasma membrane by its N-terminal end. In
contrast to SI and LPH, no intracellular or extracellular
proteolytic processing has been documented in humanMGAM.
The genomic and complementary DNA sequences for human
MGAM have revealed the presence of at least two different
subunits in the mature protein, which display high homology
to the respective subunits of the SI complex and contain one
potential active site each. These similarities have led to the
suggestion that MGAM and SI are related proteins arising by
duplication of an ancestral gene. Because of the relatively recent
description of the MGAM gene and its complementary DNA,
no studies on the hormonal or genetic regulation of its
messenger RNA (mRNA) expression exist. In addition, in most
studies, no attempts to differentiate MGAM maltase and
amylolytic activities from those of SI complex have been
performed, hampering an accurate evaluation of the effects of
feeding and hormone stimuli on the synthesis of the MGAM
protein. These limitations are particularly important in human
beings, in whom MGAM contributes to a small fraction of the
maltase activity [10]. The effects deduced from the differential
changes of sucrase and maltase activities have suggested that
MGAM expression and activity often follow that of its
complementary enzyme, SI. The symptoms of MGAM are
poorly defined. MGAM deficiency may cause chronic diarrhea
in young children. Although the osmolar force of starch is less
than that of sucrose or lactose because of its larger molecular
weight, starch-elimination diets relieved diarrhea in the reported
cases.
Glucose-Galactose Malabsorption
Glucose-galactose malabsorption (GGM) is a rare autoso-
mal recessive disorder that causes severe life-threatening
chronic diarrhea, because of a mutation in the gene SGLT1
that codes for a transporter responsible for the tight
coupling of two Na+ ions and one glucose or galactose
molecule across the membrane during one catalytic turn-
over [12••, 13•]. The basolateral Na-K-ATPase pump
maintains the low intracellular Na+ concentration, and this
results in the absorption of Na+, Cl−, HCO3
−, sugar, and
water across the epithelium. In patients with GGM, more
than 50 mutations in the SGLT1 gene have been identified.
The malabsorbed glucose and galactose and the derived
short-chain fatty acids (SCFA) that reach the colon
determine an osmotic diarrhea. All missense mutations that
do not impair sugar transport, Phe405Ser and His615Gln,
are not conserved and rarely occur in the general
population. In contrast, the Asn51Ser variant occurs in the
general population at a frequency of 4% [12••, 13•].
Fructose Malabsorption
Although the ability of GLUT5 to transport fructose is well
established, there remains insufficient evidence confirming
that GLUT5 represents the main fructose facilitative carrier
in the intestine [14]. Recent studies have identified GLUT7
as a high affinity glucose and fructose carrier on the brush
border membrane of the enterocytes in the distal intestine.
Recent studies also suggest a role of GLUT2 in the
absorption of large amounts of fructose across the enter-
ocytes of rats [15]. Studies performed in rodents have
confirmed that GLUT5 expression is regulated in a tissue-
and development-specific manner and is induced by dietary
fructose [3••]. GLUT5 is found at very low levels prior to
weaning, and increases dramatically in weaned animals
[3••]. However, an analysis of the age dependence of
GLUT5 levels has not been performed in humans.
Congenital Chloride-Losing Diarrhea
Congenital chloride-losing diarrhea (Online Mendelian
Inheritance in Man [OMIM] 126650) is a typical clinical
model of the CDD subgroup that is caused by altered
absorption and transport of nutrients and electrolytes [16••].
The main clinical symptom is a lifetime watery diarrhea
with high Cl− content and low pH, causing dehydration and
hypochloremic metabolic alkalosis. Congenital chloride-
losing diarrhea (CCD) may be fatal, if not adequately
treated. Long-term prognosis is generally favorable, but
complications such as renal disease, hyperuricemia, ingui-
nal hernias, spermatoceles, and male subfertility are
possible. Individual variation in the clinical picture of
congenital chloride-losing diarrhea is common, and some
mild cases have been diagnosed in adulthood [16••]. This
rare genetic disease is caused by mutations in the gene
encoding the solute-linked carrier family 26-member A3
(SLC26A3) protein, which acts as a plasma membrane
anion exchanger for Cl− and HCO3
−. The SLC26A3 gene
maps close to the CFTR gene (cystic fibrosis transmembrane
conductance regulator) on chromosome 7 [16••]. In ethnic
groups in which the disease is frequent, there is a single
mutation: in Finland, the p.V317del mutation affects up to
90% of alleles; in Saudi Arabia and Kuwait, p.G187X is
present in more than 90% of altered chromosomes; in
Poland, 50% of alleles carry the I675-676ins mutation
(official nomenclature: c.2022_2024dup–p.I675dup). In dif-
ferent ethnic groups, a wide genetic heterogeneity has been
found [16••]. Little is known about the mechanism by which
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these mutations undermine function. The C-terminal con-
served domain, called “STAS,” ensures the correct location
of the SLC26A3 protein on the apical membrane of
enterocytes, where it interacts with the R-domain of the
CFTR gene. Mutations in the STAS domain cause mis-
trafficking and cytosol retention of SLC26A3 protein, leading
to reduced levels of the protein at the plasma membrane.
Treatment with the SCFA butyrate is able to increase
expression of SLC26A3, thereby reducing fecal ion loss [3••].
Congenital Sodium Diarrhea
Congenital sodium diarrhea (CSD; OMIM 270420) is a rare
disorder characterized by severe diarrhea consequent to
sodium malabsorption, with consequent hyponatremia and
metabolic acidosis [17]. High mortality due to electrolytic
alterations has been reported in the few cases described so
far. Studies based on the “candidate gene” approach failed
to identify the disease-gene among the 6 known isoforms of
sodium-proton exchangers (NHE 1–6). However, the gene
of the syndromic form of CSD, namely SPINT2, was
recently identified [2••, 3••]. The syndromic form of CSD is
characterized by choanal or anal atresia, hypertelorism and
corneal erosions, double kidney, cleft palate, and digital
anomalies. No mutations have been identified in the
SPINT2 gene in patients bearing the classic form of the
disease.
Fanconi-Bickel Syndrome
Fanconi-Bickel syndrome (FBS; OMIM 227810) is a very
rare autosomal recessive disorder that is characterized by
carbohydrate malabsorption, tubular nephropathy, hepato-
megaly, and glucose metabolism disorders. Homozygous
mutations in the facilitative glucose transporter,GLUT2, have
been identified in patients with FBS. Functional studies have
not been performed to confirm that these mutations alter the
functionality of GLUT2 protein, and the mechanism by
which mutation in the carrier GLUT2 affects glucose
metabolism is not well understood. Impaired hepatocyte
transport and glucose-sensing mechanism by pancreatic β
cells are a possible explanation. In the intestine, the presence
of a GLUT2-independent pathway for glucose transport is
plausible. In fact, severe osmotic diarrhea is generally not
associated with FBS, and evidence from mice suggests that
mutations in GLUT2 do not particularly affect monosaccha-
ride transport across the enterocyte [18].
Acrodermatitis Enteropathica
Primary acrodermatitis enteropathica (PAE; OMIM 201100)
is a rare autosomal recessive disease of impaired intestinal
absorption of zinc [19]. A candidate gene has been identified,
which encodes for a member of the zinc- and iron-regulated
transporter family of proteins (ZIP4). ZIP4 is expressed on
the apical membrane of epithelia in the intestine and kidney.
Although patients with PAE have a reduced capacity to
absorb luminal zinc, their responsiveness to oral zinc load
raises the possibility that they retain a redundant, but less
efficient, zinc transport mechanism in the intestine [19].
Lysinuric Protein Intolerance
Lysinuric protein intolerance (LPI; OMIM 222700) is
transmitted in an autosomal recessive manner resulting
from mutations in the SL7A7 gene, which encodes for the
cationic amino acid transporter y+LAT1 [20]. The y+LAT1
transporter is situated on the basolateral membrane of the
enterocyte and renal tubules, and transports the cytoplasmic
basic amino acids (lysine, arginine, ornithine) in exchange
for sodium and neutral amino acids. More than 30
mutations have been identified in the SLC7A7 gene. Founder
mutations have been identified in Finnish, Japanese, and
Italian patients. Ornithine and arginine are important urea
cycle intermediates that fail to exit the epithelial cells of
patients with LPI. Their relative deficiency, during a high-
protein milk diet, results in urea cycle dysfunction that leads
to hyperammonemia and subsequent alteration in mental
status [20].
Shwachman-Diamond Syndrome
Shwachman-Diamond Syndrome (SDS; OMIM 260400)
is a very rare autosomal recessive disorder (frequency of
1:76000) with clinical features that include hematological
dysfunction, pancreatic exocrine insufficiency, and
skeletal abnormalities [21]. Patients with SDS are signifi-
cantly predisposed to the development of hematological
abnormalities, including cytopenias of one or more
lineages, myelodysplasia, and acute leukemia. SDS-
associated mutations were recently described in a gene
designated SBDS (Shwachman-Bodian-Diamond syn-
drome) that encodes a member of a highly conserved
protein family of unknown function with orthologues in
diverse species, including Archaea, plants, and eukaryotes
but not Eubacteria [21]. Indirect evidence supports the
hypothesis that the SBDS protein family may function in
RNA metabolism. At least 90% of affected individuals
carry one common conversion mutation, whereas 50% are
compound heterozygotes with respect to the K62X and
C84Cfs mutations. Strikingly, no homozygotes for the
K62X mutation were identified, suggesting that this may
be a lethal mutation. Alleles from affected individuals who
do not have the common conversion mutations carry
additional frameshift and missense mutations in the SBDS
coding region [21].
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Cystic Fibrosis
Cystic fibrosis is caused by mutations in the CFTR gene,
which encodes a multifunctional protein that is expressed in
many epithelial tissues [22]. CFTR has a pivotal role in
regulating epithelial fluid balance. CFTR is a cyclic
adenosine monophosphate (cAMP)-activated chloride chan-
nel that regulates other ion channels, notably the epithelial
sodium channel ENaC. Cystic fibrosis is characterized
functionally by the absence of a cAMP-regulated chloride
secretory pathway. More than 95% of patients with cystic
fibrosis fail to produce digestive enzymes in the pancreas,
resulting in pancreatic insufficiency. Complications at the
pancreatic level are responsible for chronic diarrhea
observed in children with cystic fibrosis. Population studies
suggest that most of the patients with pancreatic insuffi-
ciency were descendents from a single mutational event at
the CFTR locus. More than a thousand mutations have been
defined in the CFTR gene to date. These mutations are
situated throughout the entire coding region of the gene and
also the promoter region, although there are regions where
mutations are more common, such as nucleotide binding
domain and regulatory domain. Patients with pancreatic
insufficiency are homozygous or compound heterozygous
for two severe mutations [22].
Enterokinase Deficiency
Enterokinase deficiency seriously impairs protein absorp-
tion. Proteinase-activated receptor 2 is present at the apical
and basolateral membrane of enterocytes; activation of this
receptor by trypsin stimulates enterocytes to secrete
eicosanoids, which act locally in the intestinal wall to
regulate epithelial growth [23]. Therefore, in addition to its
purely digestive role, enterokinase localization on the
luminal surface of the duodenal villi possibly contributes
to enterocyte growth by generating active trypsin on the cell
surface. The human genetic locus appears to be close to the
gene for β-amyloid precursor protein at band 21q.21.2 [23].
The human proenteropeptidase gene consists of 25 exons
(24 introns) and it spans 88 kb. Mutations in the duodenase
gene, resulting in defective activation of proenteropepti-
dase, may possibly lead to disease similar to enterokinase
deficiency. Only 13 cases of primary enterokinase
deficiency have been reported. Three additional patients
were reported with a similar clinical picture, but with
unmeasured intestinal enterokinase activity [23]. All
mutations identified in the proenteropeptidase gene are
null mutations that predict the absence of a correctly
formed active site. Prognosis is good with adequate
treatment. Pancreatic enzyme replacement is indicated in
patients with intestinal enterokinase deficiency. Treatment
of enterokinase deficiency involves no dietary restrictions
or recommendations after starting proper pancreatic
enzyme replacement therapy. Individualized dosing is
based on age, body weight, and symptoms.
Chylomicron Retention Disease and Anderson Disease
Although several disorders are caused by genetic defects in
vesicle-mediated trafficking, only chylomicron retention
disease (CMRD; OMIM 246700) and Anderson disease
(OMIM 607689) primarily involve the intestine [24, 25].
CMRD and Anderson disease are allelic and closely related
autosomal recessive diseases that appear with severe lipid
malabsorption, chronic diarrhea, failure to thrive, and
hypocholesterolemia caused by hypobetalipoproteinemia.
Microvacuolization of enterocytes caused by retention of
chylomicrons and lipid vacuoles in the cytoplasm are
typical features at histologic examination. The causative
gene, SARIB, encodes a small GTPase associated with
COPII vesicles involved in endoplasmic reticulum-to-Golgi
transport and in chylomicron and low-density lipoprotein
transport [3••, 24, 25].
Congenital Bile Acid Diarrhea
Because of a defect in the Na+-dependent bile salt
transporter (ASBT) coded by the SLC10A2 gene [26],
congenital bile acid diarrhea (PBAM; OMIM 601295) is a
rare disorder transmitted in an autosomic recessive fashion
and characterized by impaired bile acid reabsorption.
Studies in mice also suggest the presence of a basolateral
taurocholate transporter. Both proteins are required to
required taurocholate reabsorption [26]. Other transporters,
NTCP and BSET, are crucial for a physiologic bile acid
cycle. Further studies are advocated to define the role of
these proteins in the pathogenesis of the disease.
Enterocyte Differentiation and Polarization
Microvillous Inclusion Disease
Microvillous inclusion disease (MID; OMIM 251850) is a
severe secretory diarrhea that usually starts shortly after
birth [27•, 28]. A late-onset form (at 3–4 months of life)
with a better outcome has been described. Pathology shows
shortened microvilli and villous atrophy with an increased
number of secretory granules within enterocytes and
membrane-bound inclusions. It was recently demonstrated
that Rab8, a small GTP-binding protein, and myosin Vb
(MYO5B) are involved in the intracellular transport of
proteins to the apical level of the intestinal epithelial cells
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[2••, 27•]. A deficit of Rab8 results in a pathological picture
almost identical to that of MID in an animal model [2••].
Interestingly, although Rab8 mRNA and protein were
absent from one MID patient’s biopsy specimen, no
mutations were identified in the Rab8 gene in patients with
MID. On the other hand, mutations in the MYO5B gene that
encoded for myosin Vb were recently found in nine
families that included members affected by MID [3••,
27•]. Myosin Vb forms a complex with Rab protein and
vesicles, and it is required for enterocyte polarization.
Myosin Vb deficiency may block the apical traffic of
intracellular vacuoles containing microvilli, thereby deter-
mining aggregation of apically bound vesicles. However,
other genetic causes of MID are possible.
Intestinal Epithelial Dysplasia
Intestinal epithelial dysplasia is a rare autosomal recessive
diarrheal disorder characterized by high morbidity and
mortality [29•]. Mutations in the EpCAM gene are
responsible for the disorder. The primary function of
EpCAM is to mediate cell-cell interaction. EpCAM is
known to recruit intracellular actin to the sites of homo-
philic contacts. EpCAM also co-localizes with E-cadherin in
areas of cell-cell junctions and directly associates with the
tight junction protein claudin-7 [2••, 29•]. The identification
of these mutations will advance our understanding of this
disorder and provide new strategies for its management.
Enteroendocrine Cell Differentiation
Enteric Anendocrinosis
Extensive evaluation of intestinal biopsies from patients with
enteric anendocrinosis (OMIM 610370) has shown severe
enteroendocrine cell dysgenesis associated with normal villus
structure and crypt-villus axis, and absence of inflammation.
The disorder is characterized by severemalabsorptive diarrhea
and a lack of intestinal enteroendocrine cells caused by loss-
of-function mutations in neurogenin-3 (NEUROG3) [30, 31].
Neurogenin-3 is a transcriptional factor that induces
differentiation of stem cells located at the base of the
crypt-villus axis into four functional cell types: epithe-
lial cells, mucus-secreting goblet cells, antimicrobial
Paneth cells, and hormone-secreting enteroendocrine
cells. Because NEUROG-3 is critical to the development
of pancreatic islet cells, patients with enteric anendocri-
nosis develop clinical evidence of diabetes (without anti-
islet antibodies) between 4 and 10 years of age. What
remains unclear is the role that enteroendocrine cells have
in facilitating the absorption of simple nutrients.
Modulation of the Intestinal Immune Response
Immune Dysregulation, Polyendocrinopathy, Enteropathy,
X-Linked Syndrome
The immune dysregulation, polyendocrinopathy, enteropathy,
X-linked syndrome (IPEX; OMIM 304930) is usually a fatal
disorder unless treated with immunosuppressive therapy and/
or bone marrow transplantation [32, 33••]. Patients with
IPEX syndrome were found to harbor mutations in the
FOXP3 gene, which is the gene altered in scurfy mice, a
mouse strain with severe autoimmunity and lymphoprolifer-
ation. The FOXP3 gene encodes scurfin, a protein predom-
inantly expressed in CD4+/CD25+ T cells that regulates T-
cell activation (T-reg cells). Ablation of FOXP3-expressing
cells in mice results in severe autoimmunity and lympho-
proliferation. Additionally, loss of expression of interleukin
(IL)-10 by FOXP3-expressing cells results in inflammation
in the gut and lung. FOXP3 coordinates the assembly of
multiple transcriptional regulators into a complex. Structural
and biochemical insights into these complex ensembles will
increase our understanding of FOXP3 function and facilitate
the development of potential applications under disease
conditions. A recently identified mutation within an
upstream non-coding region of FOXP3 results in a variant
of IPEX syndrome that is associated with autoimmune and
severe immunoallergic symptoms (ie, food allergy, hyper-
IgE, atopic dermatitis, and hypereosinophilia). A syndrome
related to IPEX was described in two patients with mutations
in the IL-2 receptor α (CD25) gene. The FOXP3 gene was
found to be wild-type in these patients. In one patient,
mutations in CD25 resulted in defective secretion of IL-10
by lymphocytes. Because IL-10 is important in the down-
regulation of inflammation, this finding suggests a possible
mechanism by which mutations in CD25 may phenocopy
IPEX [32, 33••].
Conclusions
The recent progress made in understanding the genetics and
pathophysiology of CDD could contribute to identification
of novel strategies for the diagnosis and treatment of these
conditions. Widespread use of efficient diagnostic tests may
reveal a higher prevalence of the disorders classified within
the CDD group than recognized currently. Additionally,
molecular technology may help clinicians to better manage
these disorders, particularly in early life, when severe
diarrhea may be life-threatening, leading to massive
dehydration and metabolic acidosis. Second-level
approaches, including in vitro functional studies, could be
useful to define the effect of a mutation and to confirm that
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a novel variant is indeed disease-causing. Nevertheless,
proteomic studies may predict the phenotype, and guide
physicians in the clinical management of CDD. Close
collaboration between clinicians and laboratory professio-
nals appears crucial for current clinical management and
future research in the field of CDD.
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